Renal: Adult Patients Clinical Research
Back to Oncology/Cancer Clinical Trials Main Page
CPMC Cancer Services
| Principal Investigator/Contact Information | Protocol Title | Patient Population | Recruitment Period |
|---|---|---|---|
| Principal Investigator: David Minor, MD Contact: Zeena Salman 415-600-1654 Email salmanz@cpmcri.org | A phase IIIb, randomized , open-label study of bevacizumab (AVASTIN) + temsirolimus (TORISEL) vs. bevacizumab + interferon-alfa as first line treatment in patients with advanced renal cell carcinoma. WYETH 3066-3311-WW Visit the advanced renal cell carcinoma study on ClinicalTrials.gov. | Subjects who have been diagnosed with advanced renal cell carcinoma (kidney cancer) | Open |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma. ECOG E2805/CTSU Visit the Unfavorable Renal Carcinoma study on ClinicalTrials.gov. | Subjects with Renal Cell Carcinoma | Open |
| Principal Investigator: CPMC Oncologists Contact: Ron Frianeza 415-600-3027 Email frianer@cpmcri.org | The BEST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTor Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma. E2804 Visit the Advanced Renal Cell Carcinoma study on ClinicalTrials.gov. | Subjects who have clear cell variant of Renal Cell Carcinoma with less that 25% of any other histology | Open |
| Principal Investigator: David Minor, MD Contact: Zeena Salman 415-600-1654 Email salmanz@cpmcri.org | A Phase II Trial of Pazopanib in Patients with Metastatic Renal Cell Carcinoma Previously Treated with Sunitinib or Bevacizumab (SCRI GU 56) Visit the Patients with Metastatic Renal Cell Carcinoma study on ClinicalTrials.gov. | Patients with metastatic or locally advanced unresectable renal cell carcinoma who have received therapy with either sunitinib or bevacizumab (with or without interferon). | Coming Soon |
Back to top